EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of CCL22 and CXCL13 as Potential Biomarkers for the Diagnosis and Assessment of Pediatric SLE and Lupus Nephritis

Xiao-Lin Chen, Yu Liu, Lu Hui, Meng-Ke Huang, Ting Liu, Yong-Mei Jiang

International Journal of Clinical Practice · 2026-01 · 2026 (1)

DOI: 10.1155/ijcp/1081360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Practice, online erschienen am 29.06.2026. Verfasst von Xiao-Lin Chen und 5 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chemokines are crucial in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). This study aimed to detect chemokines and chemokine‐related cytokines in SLE patients with and without LN, as well as healthy controls, to identify potential biomarkers for clinical diagnosis.

Methods

Luminex technology was used to measure 40 chemokines and chemokine‐related cytokines in serum and urine samples from SLE patients under 18 years. Chemokine concentrations were compared, and their correlation with the SLE Disease Activity Index (SLEDAI) was evaluated. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis.

Results

Significant differences in the serum levels of CCL22, CCL23, and CXCL13, and urine levels of CCL7, CCL19, CCL22, CXCL2, CXCL5, and CXCL13, as well as chemokine‐related cytokines IL‐2, IL‐4, TNF‐α, and GM‐CSF, were observed between the SLE, LN, and healthy control groups. CCL22 and CXCL13 exhibited specific expression in both serum and urine samples and were significantly correlated with SLEDAI. Diagnostic performance assessments show that CCL22 and CXCL13 have excellent diagnostic efficacy for both SLE and LN. Importantly, the combination of CCL22 and CXCL13 significantly improved the accuracy of SLE diagnosis and enhanced the differential diagnosis of LN.

Conclusion

Our study suggests that the combined use of CCL22 and CXCL13 could serve as promising biomarkers for diagnosing SLE and LN.

Zitieren

APA

Chen, X., Liu, Y., Hui, L., Huang, M., Liu, T., & Jiang, Y. (2026). Combination of CCL22 and CXCL13 as Potential Biomarkers for the Diagnosis and Assessment of Pediatric SLE and Lupus Nephritis. International Journal of Clinical Practice, 2026(1). https://doi.org/10.1155/ijcp/1081360

Vancouver

Chen X, Liu Y, Hui L, Huang M, Liu T, Jiang Y. Combination of CCL22 and CXCL13 as Potential Biomarkers for the Diagnosis and Assessment of Pediatric SLE and Lupus Nephritis. International Journal of Clinical Practice. 2026;2026(1). doi:10.1155/ijcp/1081360

BibTeX
@article{Chen2026,
  author = {Chen, Xiao-Lin and Liu, Yu and Hui, Lu and Huang, Meng-Ke and Liu, Ting and Jiang, Yong-Mei},
  title = {Combination of CCL22 and CXCL13 as Potential Biomarkers for the Diagnosis and Assessment of Pediatric SLE and Lupus Nephritis},
  journal = {International Journal of Clinical Practice},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ijcp/1081360}
}
Kostenlos starten →